Not to be used for primary or secondary prevention of CV disease. Increased risk of venous thromboembolism. Discontinue at least 72 hr prior to & during prolonged immobilization (eg, post surgical recovery, prolonged bed rest) & resume therapy only after fully ambulatory. Consider risk-benefit balance in women at risk of thromboembolic disease for other reasons eg, CHF, superficial thrombophlebitis & active malignancy; at risk for stroke (eg, prior stroke or transient ischemic attack, atrial fibrillation, HTN, cigarette smoking). History of breast cancer & use of oral estrogen-induced hypertriglyceridemia (>5.6 mmol/L). Unexplained uterine bleeding & breast abnormality. Monitor serum bilirubin, γ-glutamyl transferase, alkaline phosphatase, ALT & AST. Not recommended for premenopausal use & use for men. Moderate & mild renal impairment. Hepatic impairment. Not recommended during pregnancy & lactation. Childn.